What’s Benitec Biopharma Limited Ads (NASDAQ:BNTC) Upside After This Short Interest Decrease?

September 17, 2017 - By Marry Poplack

 What's Benitec Biopharma Limited Ads (NASDAQ:BNTC) Upside After This Short Interest Decrease?

The stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered a decrease of 19.38% in short interest. BNTC’s total short interest was 74,900 shares in September as published by FINRA. Its down 19.38% from 92,900 shares, reported previously. With 11,600 shares average volume, it will take short sellers 7 days to cover their BNTC’s short positions. The short interest to Benitec Biopharma Limited Ads’s float is 1.06%.

The stock decreased 0.98% or $0.02 on September 15, reaching $2.03. About 10,286 shares traded. Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) has risen 56.67% since September 17, 2016 and is uptrending. It has outperformed by 39.97% the S&P500.

Benitec Biopharma Limited is a biotechnology company. The company has market cap of $20.92 million. The Firm is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property ; development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. It currently has negative earnings. The Company’s In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.

More recent Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) news were published by: Marketwatch.com which released: “2.04” on December 30, 2013. Also Benzinga.com published the news titled: “Arbutus Biopharma Taken Off Of Chardan’s Sell List” on June 16, 2016. Quotes.Wsj.com‘s news article titled: “Benitec Biopharma Ltd. ADR” with publication date: July 31, 2015 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: